What is InVitro International?
Founded in 1985 and headquartered in Placentia, California, InVitro International operates at the intersection of biotechnology and regulatory compliance. The firm specializes in the development and commercialization of non-animal testing systems, most notably the Irritection Assay System and Corrositex. These proprietary platforms provide high-fidelity, cost-effective alternatives to traditional animal testing, enabling global clients to meet stringent safety standards such as OECD, GHS, and REACH. By prioritizing in-vitro science, the company has established itself as a critical partner for organizations seeking to navigate the complex requirements of modern toxicity and irritation assessment while adhering to cruelty-free mandates.
How much funding has InVitro International raised?
InVitro International has raised a total of $101K across 1 funding round:
Debt
$101K
Debt (2021): $101K with participation from PPP
Key Investors in InVitro International
PPP
Public-Private Partnership
What's next for InVitro International?
With this recent capital injection, InVitro International is well-positioned to accelerate its research and development pipeline and expand its global laboratory service footprint. The strategic focus will likely shift toward enhancing the sensitivity and throughput of its existing assay kits to capture a larger share of the chemical, cosmetic, and pharmaceutical testing markets. As regulatory bodies worldwide continue to tighten restrictions on animal-based testing, InVitro International's established infrastructure and proven methodology provide a robust foundation for sustained growth. The company is expected to leverage this financing to deepen its penetration into emerging markets where demand for standardized, ethical safety testing is rising rapidly, ensuring its continued leadership in the non-animal testing industry.
See full InVitro International company page
